RiverPark Advisors’s ZyVersa Therapeutics ZVSA Stock Holding History

RiverPark Advisors’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,000	Closed	-$7M	–	103
2022 Q3	$7M	Hold	2,000	–	–	2.27%	9
2022 Q2	$6.95M	Hold	2,000	–	–	2.2%	12
2022 Q1	$6.94M	Buy	+2,000	New	+$6.92M	1.27%	28

Other funds holding ZVSA

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

RiverPark Advisors's ZVSA Position: Q4 2022 in Review

RiverPark Advisors sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 2,000 shares — an estimated $7M sold.

RiverPark Advisors first reported a position in ZVSA in Q1 2022 and held it in 3 quarters. The position peaked at $7M in Q3 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

RiverPark Advisors reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
RiverPark Advisors sold 2,000 ZyVersa Therapeutics shares in Q4 2022, an estimated $7M.
RiverPark Advisors first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 3 quarters.
RiverPark Advisors's ZyVersa Therapeutics position peaked at $7M in Q3 2022.
2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on RiverPark Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.